Johnson & Johnson’s Coronavirus Vaccine Data Isn’t as Bad as It First Appears

1 min read

In this video from Motley Fool Live, recorded on Feb. 1, Contributors Brian Orelli and Keith Speights discuss the phase 3 clinical trial results for Johnson & Johnson‘s (NYSE: JNJ) coronavirus vaccine. While the efficacy wasn’t as good as the vaccine from Moderna (NASDAQ: MRNA) and the one from Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), Johnson & Johnson’s clinical trial had more exposure to the new coronavirus variants. Johnson & Johnson’s one-shot format also makes it easier to deliver to rural areas.

Brian Orelli: First off, we have phase 3 data from Johnson & Johnson that was released last week. In the United States it had a 72% efficacy. In Latin America 66%. In South Africa, all the way down at 57%. I don’t think that’s really too surprising considering this new variant in South Africa and Latin America, and this was designed to express the original spike protein. It’s not too surprising to see lower efficacy in South Africa and Latin America than in the United States. Overall, 66% efficacy when you average those three out based on how many people were in each of the areas.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Is Google’s New Privacy Push Another Nail in the Coffin for Facebook?

Next Story

Forget Moderna! This Is a More Lucrative Coronavirus Stock

Latest from Blog